Livsmed Inc (KOSDAQ:491000)
South Korea · Delayed Price · Currency is KRW 41,300
+700 (1.72%)
At close: Jun 12, 2026
Livsmed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 51,725 | 51,192 | 27,121 | 17,267 | 9,678 | |
Revenue Growth (YoY) | 61.66% | 88.75% | 57.07% | 78.42% | - |
Cost of Revenue | 23,677 | 21,658 | 12,575 | 7,788 | 4,201 |
Gross Profit | 28,047 | 29,534 | 14,547 | 9,479 | 5,477 |
Selling, General & Admin | 35,908 | 36,004 | 28,731 | 24,113 | 17,328 |
Research & Development | 14,470 | 14,160 | 10,697 | 7,640 | 4,529 |
Amortization of Goodwill & Intangibles | 334.92 | 298.71 | 233.31 | 179.03 | 139.14 |
Other Operating Expenses | 803.17 | 722.95 | 634.04 | 818.29 | 434.95 |
Operating Expenses | 52,399 | 52,177 | 41,051 | 33,390 | 22,567 |
Operating Income | -24,352 | -22,642 | -26,504 | -23,912 | -17,090 |
Interest Expense | -822.33 | -822.33 | -8,613 | -7,387 | -5,192 |
Interest & Investment Income | 302 | 302 | 740.26 | 193.78 | 43.33 |
Currency Exchange Gain (Loss) | -235.71 | -235.71 | 1,304 | 99.34 | 330.94 |
Other Non Operating Income (Expenses) | 2,649 | 524.73 | 7,489 | -26,015 | -37,112 |
EBT Excluding Unusual Items | -22,459 | -22,874 | -25,585 | -57,021 | -59,019 |
Gain (Loss) on Sale of Assets | - | - | - | 0.99 | - |
Pretax Income | -22,459 | -22,874 | -25,585 | -57,021 | -59,019 |
Net Income | -22,459 | -22,874 | -25,585 | -57,021 | -59,019 |
Net Income to Common | -22,459 | -22,874 | -25,585 | -57,021 | -59,019 |
Shares Outstanding (Basic) | 23 | 22 | 17 | 14 | 13 |
Shares Outstanding (Diluted) | 23 | 22 | 17 | 14 | 13 |
Shares Change (YoY) | 26.89% | 32.88% | 17.94% | 10.39% | - |
EPS (Basic) | -979.37 | -1030.07 | -1530.99 | -4024.24 | -4597.99 |
EPS (Diluted) | -979.37 | -1030.07 | -1530.99 | -4024.24 | -4597.99 |
Free Cash Flow | -46,151 | -41,973 | -32,009 | -27,020 | -18,535 |
Free Cash Flow Per Share | -2012.55 | -1890.19 | -1915.40 | -1906.97 | -1443.98 |
Gross Margin | 54.22% | 57.69% | 53.64% | 54.90% | 56.59% |
Operating Margin | -47.08% | -44.23% | -97.72% | -138.48% | -176.59% |
Profit Margin | -43.42% | -44.68% | -94.34% | -330.23% | -609.85% |
Free Cash Flow Margin | -89.22% | -81.99% | -118.02% | -156.49% | -191.52% |
EBITDA | -21,237 | -19,908 | -24,858 | -22,877 | -16,362 |
EBITDA Margin | -41.06% | -38.89% | -91.65% | -132.49% | -169.06% |
D&A For EBITDA | 3,115 | 2,734 | 1,647 | 1,035 | 728.17 |
EBIT | -24,352 | -22,642 | -26,504 | -23,912 | -17,090 |
EBIT Margin | -47.08% | -44.23% | -97.72% | -138.48% | -176.59% |
Advertising Expenses | - | 1,831 | 1,665 | 1,169 | 1,319 |